Next 10 |
--INVOKE-2 is the first global Phas e 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative stud...
2024-07-26 15:00:38 ET More on the markets Is It Time To Turn Intermediate Term Bearish On Stocks? SPY: Don't Be The 'Greater Fool' SPY: Good, But Not The Best Wells Fargo says S&P 500 must drop another 2% before discussing a bounce Sector ranking...
SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company’s TREM2 and progranulin programs at the upcoming Alzheimer's Associatio...
2024-07-12 16:48:36 ET Summary Alector's lead pipeline assets are for challenging brain disorders. Ample liquidity assures that Alector can develop its lead assets over the near term. Its lead pipeline candidates generate milestone revenues. With a high expense profile and...
SOUTH SAN FRANCISCO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a corporate presentation at the H.C. Wainwright 5 th Annual Neuro Pers...
SOUTH SAN FRANSISCO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will host a virtual event to discuss Alector Brain Carrier, a proprietary, versatile blood-brain barrier (BBB...
SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a fireside chat at the Goldman Sachs 45 th Annual Global Healthcare Co...
2024-05-19 01:10:48 ET Summary Anti-inflammatory drugs are likely to have limited effects on Alzheimer's disease because they are not stopping early oxidation and nitration. Neuroinflammation in Alzheimer's disease is primarily caused by oxidative and nitrosative stress. Inhib...
2024-05-08 17:46:02 ET More on Alector Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript Alector GAAP EPS of -$0.49 beats by $0.28, revenue of $15.2M beats by $6.36M Seeking Alpha’s Quant Rating on Alector Historical earnings data for Alector ...
Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer’s disease, on track for Q4 2024 Strengthened leadership team with key appointments: Neil Berkley, M.S., M.B.A., named Chief Business Officer; Errol De Souza, Ph.D....
News, Short Squeeze, Breakout and More Instantly...
--INVOKE-2 is the first global Phas e 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative stud...
SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company’s TREM2 and progranulin programs at the upcoming Alzheimer's Associatio...
SOUTH SAN FRANCISCO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a corporate presentation at the H.C. Wainwright 5 th Annual Neuro Pers...